DMK Pharmaceuticals Corporation (DMKPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 23, 2025, 8:00 PM EDT

DMK Pharmaceuticals Company Description

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.

The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder.

Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.

The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023.

The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

The plan was later approved as Chapter 11 liquidation on October 28, 2024.

DMK Pharmaceuticals Corporation
CountryUnited States
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees12

Contact Details

Address:
11682 El Camino Real
San Diego, Delaware 92130
United States
Phone858 997 2400
Websitedmkpharmaceuticals.com

Stock Details

Ticker SymbolDMKPQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS00547W3079
SIC Code2834

Key Executives

NamePosition
Eddie Wabern GloverChief Executive Officer of US Compounding Inc
Seth Abraham CohenChief Restructuring Officer